NeuroSense Advances PrimeC Toward Potential ALS Approval
TEL AVIV, Israel, Aug. 31, 2026 NeuroSense Therapeutics Ltd. announced an accelerated and capital-efficient development strategy for PrimeC, its...
Amyotrophic Lateral Sclerosis
Advertisement
Cellenkos Wins FDA Fast Track for CK0803 in ALS
Houston, Texas, Aug 27, 2026 Cellenkos, Inc. has received FDA Fast Track designation for CK0803, an investigational allogeneic, cord...
Clene Advances CNM-Au8 Toward ALS Accelerated Approval
SALT LAKE CITY, Utah, August 10, 2026 Clene Inc. announced new biomarker analyses for CNM-Au8 that will be included...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
AL-S Pharma Reports Positive Phase 2 AP-101 Data at ENCALS 2026
ZURICH, Switzerland, June 24, 2026 AL-S Pharma AG announced positive Phase 2 clinical results for its lead investigational antibody...
Advertisements
Leal Therapeutics Doses First ALS Patient with LTX-002
WORCESTER, Mass. | June 23, 2026 Leal Therapeutics has announced that the first patient has been dosed in the...
Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
Corcept Therapeutics Reports ALS Survival Breakthrough
REDWOOD CITY, California, April 30, 2026 Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2...
Trethera Expands ALS Trial with MGH for TRE-515
LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...
Advertisement
